MRP3: A molecular target for human glioblastoma multiforme immunotherapy

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kuan, Chien Tsun ^a   Wakiya, Kenji ^a   Herndon II, James E ^a   Lipp, Eric S ^a   Pegram, Charles N ^a   Riggins, Gregory J ^b   Rasheed, Ahmed ^a   Szafranski, Scott E ^a   McLendon, Roger E ^a   Wikstrand, Carol J ^c   Bigner, Darell D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c SABA UNIVERSITY SCHOOL OF MEDICINE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; BEVACIZUMAB; CARMUSTINE; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G ANTIBODY; IRINOTECAN; MESSENGER RNA; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 3 ANTIBODY; PROTEIN ANTIBODY; RNA; TEMOZOLOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; VINCRISTINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 3;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENETIC ANALYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RABBIT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; TUMOR BIOPSY; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BRAIN; BRAIN TUMOR; CANCER STAGING; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; PROGNOSIS; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956461668     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-468     Document Type: Article

References (62)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996. 10.1056/NEJMoa043330, 15758009.
2. Waldmann TA. Monoclonal antibodies in diagnosis and therapy. Science 1991, 252:1657-1662. 10.1126/science.2047874, 2047874.
3. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 2009, 16:11-20. 10.1158/1078-0432.CCR-09-2345, 20028761.
4. Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD. Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 2004, 4:1453-1471. 10.1517/14712598.4.9.1453, 15335313.
5. Kuan CT, Wikstrand CJ, Bigner DD. EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol 2000, 17:71-78. 10.1007/BF02482738, 11210174.
6. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, et al. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. J Clin Oncol 1998, 16:2202-2212.
7. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys 1992, 22:225-230.
8. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ, et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995, 55:3140-3148.
9. Kuan CT, Wakiya K, Dowell JM, Herndon JE, Reardon DA, Graner MW, Riggins GJ, Wikstrand CJ, Bigner DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin Cancer Res 2006, 12:1970-1982. 10.1158/1078-0432.CCR-05-2797, 16609006.
10. Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF, Wikstrand CJ. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol 1981, 40:201-229. 10.1097/00005072-198105000-00001, 6260907.
11. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999, 1:44-51. 1919466, 11550301.
12. Wikstrand CJ, Bigner SH, Bigner DD. Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 1983, 43:3327-3334.
13. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995, 270:484-487. 10.1126/science.270.5235.484, 7570003.
14. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. 10.1126/science.1164382, 2820389, 18772396.
15. Loging WT, Lal A, Siu IM, Loney TL, Wikstrand CJ, Marra MA, Prange C, Bigner DD, Strausberg RL, Riggins GJ. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000, 10:1393-1402. 10.1101/gr.138000, 310902, 10984457.
16. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 2001, 33:493-501. 10.1023/A:1012827221844, 11804191.
17. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000, 92:1295-1302. 10.1093/jnci/92.16.1295, 10944550.
18. Donner MG, Keppler D. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver. Hepatology 2001, 34:351-359. 10.1053/jhep.2001.26213, 11481620.
19. Rost D, Konig J, Weiss G, Klar E, Stremmel W, Keppler D. Expression and localization of the multidrug resistance proteins MRP2 and MRP3 in human gallbladder epithelia. Gastroenterology 2001, 121:1203-1208. 10.1053/gast.2001.28648, 11677213.
20. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK, Elferink RP, van der Valk P, Borst P, Scheper RJ. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 2002, 82:193-201.
21. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999, 96:6914-6919. 10.1073/pnas.96.12.6914, 22016, 10359813.
22. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 2001, 276:46400-46407. 10.1074/jbc.M107041200, 11581266.
23. Zeng H, Bain LJ, Belinsky MG, Kruh GD. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999, 59:5964-5967.
24. Decleves X, Fajac A, Lehmann-Che J, Tardy M, Mercier C, Hurbain I, Laplanche JL, Bernaudin JF, Scherrmann JM. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002, 98:173-180. 10.1002/ijc.10135, 11857404.
25. Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T, Kuwano M. Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 2001, 92:211-219.
26. Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 2002, 35:305-314. 10.1016/S0169-5002(01)00430-5, 11844606.
27. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997, 57:3537-3547.
28. Tada Y, Wada M, Migita T, Nagayama J, Hinoshita E, Mochida Y, Maehara Y, Tsuneyoshi M, Kuwano M, Naito S. Increased expression of multidrug resistance-associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer 2002, 98:630-635. 10.1002/ijc.10246, 11920626.
29. van der Kolk DM, de Vries EG, Noordhoek L, van den Berg E, van der Pol MA, Muller M, Vellenga E. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 2001, 15:1544-1553. 10.1038/sj.leu.2402236, 11587212.
30. Young LC, Campling BG, Cole SP, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 2001, 7:1798-1804.
31. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, et al. Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005, 74:113-121. 10.1007/s11060-004-6152-7, 16193381.
32. Ros JE, Roskams TA, Geuken M, Havinga R, Splinter PL, Petersen BE, LaRusso NF, van der Kolk DM, Kuipers F, Faber KN, et al. ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut 2003, 52:1060-1067. 10.1136/gut.52.7.1060, 1773728, 12801967.
33. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034. 10.1038/nm0901-1028, 11533706.
34. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002, 20:11-20. 10.1002/stem.200011, 11796918.
35. Jin F, Zhao L, Zhao HY, Guo SG, Feng J, Jiang XB, Zhang SL, Wei YJ, Fu R, Zhao JS. Comparison between cells and cancer stem-like cells isolated from glioblastoma and astrocytoma on expression of anti-apoptotic and multidrug resistance-associated protein genes. Neuroscience 2008, 154(2):541-50. 10.1016/j.neuroscience.2008.03.054, 18462887.
36. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001, 61:6459-6466.
37. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res 1999, 59:2532-2535.
38. Scheffer GL, Kool M, Heijn M, de Haas M, Pijnenborg AC, Wijnholds J, van Helvoort A, de Jong MC, Hooijberg JH, Mol CA, et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000, 60:5269-5277.
39. Kleihues P, Burger PC, Scheithauer BW, Zülch KJ. Histological typing of tumours of the central nervous system 1993, Berlin; New York: Springer-Verlag, 2.
40. Hipfner DR, Almquist KC, Leslie EM, Gerlach JH, Grant CE, Deeley RG, Cole SP. Membrane topology of the multidrug resistance protein (MRP). A study of glycosylation-site mutants reveals an extracytosolic NH2 terminus. J Biol Chem 1997, 272:23623-23630. 10.1074/jbc.272.38.23623, 9295302.
41. Fromm MF, Leake B, Roden DM, Wilkinson GR, Kim RB. Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. Biochim Biophys Acta 1999, 1415:369-374. 10.1016/S0005-2736(98)00233-8, 9889399.
42. Wikstrand CJ, Stanley SD, Humphrey PA, Pegram CN, Archer GE, Kurpad S, Shibuya M, Bigner DD. Investigation of a synthetic peptide as immunogen for a variant epidermal growth factor receptor associated with gliomas. J Neuroimmunol 1993, 46:165-173. 10.1016/0165-5728(93)90246-U, 8360327.
43. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997, 57:4130-4140.
44. Akita H, Suzuki H, Hirohashi T, Takikawa H, Sugiyama Y. Transport activity of human MRP3 expressed in Sf9 cells: comparative studies with rat MRP3. Pharm Res 2002, 19:34-41. 10.1023/A:1013699130991, 11837698.
45. Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe T, Wada M, Kagotani K, et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 1998, 252:103-110. 10.1006/bbrc.1998.9546, 9813153.
46. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 2005, 65:11419-11428. 10.1158/0008-5472.CAN-05-1271, 16357150.
47. Nies AT, Jedlitschky G, Konig J, Herold-Mende C, Steiner HH, Schmitt HP, Keppler D. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004, 129:349-360. 10.1016/j.neuroscience.2004.07.051, 15501592.
48. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994, 91:2076-2080. 10.1073/pnas.91.6.2076, 43312, 8134351.
49. Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon JE, Pastan I, Raghavan R, Sampson JH. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J Neurooncol 2009, 98:1-7. 10.1007/s11060-009-0046-7, 19898744.
50. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD. Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 1999, 18:451-464. 10.1023/A:1006354102377, 10855788.
51. Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2010, 127:598-611. 10.1002/ijc.25062, 19937796.
52. Capone PM, Papsidero LD, Chu TM. Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Cancer Inst 1984, 72:673-677.
53. Eijdems EW, De Haas M, Coco-Martin JM, Ottenheim CP, Zaman GJ, Dauwerse HG, Breuning MH, Twentyman PR, Borst P, Baas F. Mechanisms of MRP over-expression in four human lung-cancer cell lines and analysis of the MRP amplicon. Int J Cancer 1995, 60:676-684. 10.1002/ijc.2910600518, 7860142.
54. Burger H, Nooter K, Zaman GJ, Sonneveld P, van Wingerden KE, Oostrum RG, Stoter G. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994, 8:990-997.
55. Lonn U, Lonn S, Nylen U, Stenkvist B. Appearance and detection of multiple copies of the mdr-1 gene in clinical samples of mammary carcinoma. Int J Cancer 1992, 51:682-686. 10.1002/ijc.2910510503, 1612774.
56. Stockel B, Konig J, Nies AT, Cui Y, Brom M, Keppler D. Characterization of the 5'-flanking region of the human multidrug resistance protein 2 (MRP2) gene and its regulation in comparison withthe multidrug resistance protein 3 (MRP3) gene. Eur J Biochem 2000, 267:1347-1358. 10.1046/j.1432-1327.2000.01106.x, 10691972.
57. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, Tien Kuo M. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. Biochem Pharmacol 2001, 61:555-563. 10.1016/S0006-2952(00)00592-X, 11239498.
58. Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, Klaassen CD. Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab Dispos 2003, 31:1315-1319. 10.1124/dmd.31.11.1315, 14570762.
59. Ogawa K, Suzuki H, Hirohashi T, Ishikawa T, Meier PJ, Hirose K, Akizawa T, Yoshioka M, Sugiyama Y. Characterization of inducible nature of MRP3 in rat liver. Am J Physiol Gastrointest Liver Physiol 2000, 278:G438-446.
60. Hirrlinger J, Konig J, Keppler D, Lindenau J, Schulz JB, Dringen R. The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. J Neurochem 2001, 76:627-636. 10.1046/j.1471-4159.2001.00101.x, 11208926.
61. Ali-Osman F, Brunner JM, Kutluk TM, Hess K. Prognostic significance of glutathione S-transferase pi expression and subcellular localization in human gliomas. Clin Cancer Res 1997, 3:2253-2261.
62. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004, 64:1220-1223. 10.1158/0008-5472.CAN-03-3137, 14973082.